For decades, some cancers were a near-certain death sentence. Now, a new generation of cancer drugs—many coming from biotech, not big pharma—is changing that. RTW’s Chris Liu discusses ASCO 2026, and breakthroughs in pancreatic cancer, lung cancer, and other hard-to-treat tumors. What's driving the progress, why is it happening now, and what does it mean for the future of cancer care?

PODCAST TEAM

Producer & Director: Devon Leaver

Editor: Dominique Guerra

Production Coordinator: Ying Yu Lin

Production Support: Annabelle Chan

Production Assistant: Nicole M. Rosales

Executive Editorial Advisor: Stephanie A. Sirota

Research Consultant: Chris Liu

Research Consultant: Julia Harper

Research Consultant: Lauren Lee

Theme Music: Yehezkel Raz

Additional Music: APM  ...